Department of Endocrinology, Bharti Hospital Karnal, Karnal, India.
Department of Medicine, Weill Cornell Medical College, Doha, Qatar.
Adv Ther. 2018 Jul;35(7):928-936. doi: 10.1007/s12325-018-0712-2. Epub 2018 May 23.
Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to insulin glargine, with similar fasting plasma glucose (FPG) and insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4-5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of insulin therapy in both type 1 and type 2 diabetes.
德谷胰岛素门冬胰岛素（IDegAsp）是首个可溶性胰岛素复方制剂，包含长效胰岛素德谷胰岛素（IDeg）和速效胰岛素门冬胰岛素（IAsp）。对于口服降糖药（OAD）控制不佳的 2 型糖尿病患者，每日一次起始德谷胰岛素门冬胰岛素治疗可提供优于甘精胰岛素的长期血糖控制，且 FPG 和胰岛素剂量相似，总体和夜间低血糖发生率更低。此外，对于先前接受胰岛素治疗的血糖控制不佳的 2 型糖尿病患者，每日两次起始德谷胰岛素门冬胰岛素治疗可有效改善糖化血红蛋白和 FPG，且低血糖发作次数更少，优于预混胰岛素和基础-餐时胰岛素治疗。对于 1 型糖尿病患者，每日一次德谷胰岛素门冬胰岛素联合两次门冬胰岛素注射与传统的基于 4-5 次注射的基础-餐时胰岛素治疗相比更为方便且有效。德谷胰岛素门冬胰岛素是 1 型和 2 型糖尿病起始胰岛素治疗的合适和合理选择。
